155748-61-1

Basic information

• Product Name: (4R)-(3',4'-Dichlorophenyl)-3,4-dihydro-2H-naphthalen-1-one
• Synonyms: (4R)-(3',4'-Dichlorophenyl)-3,4-dihydro-2H-naphthalen-1-one;(R)-4-(3,4-Dichlorophenyl)-1-tetralone;Sertraline EP IMpurity F;Sertrakine Tetralone IMpurity
• CAS NO: 155748-61-1
• Molecular Formula: C₁₆H₁₂Cl₂O
• Molecular Weight: 291
• Product Categories: Chiral Reagents;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 155748-61-1.mol
• Article Data: 11

Chemical Properties

• Appearance: /
• Storage Temp.: Refrigerator
• Solubility: Benzene (Slightly), Chloroform (Slightly), Methanol (Slightly)
• CAS DataBase Reference: (4R)-(3',4'-Dichlorophenyl)-3,4-dihydro-2H-naphthalen-1-one(CAS DataBase Reference)
• NIST Chemistry Reference: (4R)-(3',4'-Dichlorophenyl)-3,4-dihydro-2H-naphthalen-1-one(155748-61-1)
• EPA Substance Registry System: (4R)-(3',4'-Dichlorophenyl)-3,4-dihydro-2H-naphthalen-1-one(155748-61-1)

Safety Data

• Hazardous Substances Data: 155748-61-1(Hazardous Substances Data)

Usage

Chemical Properties

Yellow Solid

Uses

(4R)-(3’,4’-Dichlorophenyl)-3,4-dihydro-2H-naphthalen-1-one (Sertraline EP Impurity F) is an intermediate in the synthesis of the drug Sertraline.

Upstream product

• 6287-38-3 3,4-dichlorobenzaldehyde 
• 79560-19-3 4-(3,4-dichlorophenyl)-3,4-dihydro-2H-naphthalen-1-one 
• 90-15-3 α-naphthol 
• 95-50-1 1,2-dichloro-benzene 
• 674767-90-9 2-methyl-propane-2-sulfinic acid [4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-naphthalen-y-yl]-amide 
• 147190-00-9 4-(3,4-Dichlorophenyl)-(4R)-hydroxybutanoic acid 1,1-dimethylethyl ester 
• 147190-01-0 (R)-4-(3,4-Dichloro-phenyl)-4-methanesulfonyloxy-butyric acid tert-butyl ester 
• 147213-96-5 (1R)-(3,4-Dichlorophenyl)-α-<3-<<(1,1-dimethylethyl)dimethylsilyl>oxy>propyl>methanesulfonate benzenemethanol 
• 147189-97-7 (1R)-(3,4-Dichlorophenyl)-4-<<(1,1-dimethylethyl)dimethylsilyl>oxy>phenylbutane 
• 147189-98-8 (1R)-(3,4-Dichlorophenyl)-1-phenylbutane-4-ol 
• 147189-95-5 (1R)-(3,4-Dichlorophenyl)-4-<<(1,1-dimethylethyl)dimethylsilyl>oxy>-1-butanol 
• 147189-99-9 4-(3,4-Dichlorophenyl)-4-oxobutanoic acid 1,1-dimethylethyl ester 
• 147189-94-4 (1R)-(3,4-Dichlorophenyl)-1,4-butanediol 
• 591-51-5 phenyllithium 

Downstream Products

• 944054-59-5 (S,E)-4-(3,4-dichlorophenyl)-2-ethylidene-3,4-dihydronapthalen-1(2H)-one 
• 674768-11-7 (1R,4R)-N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-naphthalen-1-yl]-formamide 
• 674768-15-1 (1S,4R)-N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-naphthalen-1-yl]-formamide 
• 944054-74-4 (S)-4-(3,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydronaphthalen-1(2H)-one 

Relevant articles and documents

Copper-Catalyzed Enantioselective Arylation via Radical-Mediated C-C Bond Cleavage: Synthesis of Chiral ω,ω-Diaryl Alkyl Nitriles

The first example of copper-catalyzed ring-opening, enantioselective arylation of cyclic ketoxime esters to access ω,ω-diaryl alkyl nitriles has been developed in high yield (up to 92% yield) with excellent enantioselectivity (up to 91% ee). Side-arm bis(oxazoline) ligand plays a significant role in this asymmetric catalytic transformation, which provides an efficient route to construct diverse chiral ω,ω-diaryl alkyl nitriles. Synthetic utility has also been demonstrated in the further derivatization of the ω,ω-diaryl alkyl nitrile to the corresponding amide.

Nickel-Catalyzed Asymmetric Reductive Cross-Coupling to Access 1,1-Diarylalkanes

An asymmetric Ni-catalyzed reductive cross-coupling of (hetero)aryl iodides and benzylic chlorides has been developed to prepare enantioenriched 1,1-diarylalkanes. As part of these studies, a new chiral bioxazoline ligand, 4-heptyl-BiOX (L1), was developed in order to obtain products in synthetically useful yield and enantioselectivity. The reaction tolerates a variety of heterocyclic coupling partners, including pyridines, pyrimidines, indoles, and piperidines.

COMBINATIONS OF ESZOPICLONE AND TRANS 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-N-METHYL-1-NAPTHALENAMINE OR TRANS 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPTHALENAMINE, AND METHODS OF TREATMENT OF MENOPAUSE AND MOOD, ANXIETY, AND COGNITIVE DISORDERS

One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., menopause, mood disorders, anxiety disorders, or cognitive disorders. The first component of the pharmaceutical composition is a sedative eszopiclone. The second component of the pharmaceutical composition is trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine. The present invention also relates to a method of treating menopause, perimenopause, mood disorders, anxiety disorders, and cognitive disorders.